Ottawa, ON – Innovative Medicines Canada (IMC) welcomes the Patented Medicine Prices Review Board (PMPRB) announcement to delay the implementation of their revised draft Guidelines as a renewed opportunity to have authentic stakeholder consultations and conduct a thorough impact analysis.
The PMPRB is urged to meaningfully consult with industry, patient groups and other stakeholders to support sustainable access to lifesaving drugs and a thriving life sciences sector. This additional time should be used to proceed with a whole-of-government approach which will help to ensure that final Guidelines support improved access to innovative medicines and treatments, clinical trials, R&D, and investment.
Without significant changes, the PMPRB revised draft Guidelines will have significant negative impact on access and will undermine the success of other government priorities such as the National Strategy for Drugs for Rare Diseases and the Biomanufacturing and Life Sciences Strategy.
IMC and its members remain committed to working with the federal government and other key stakeholders to ensure a robust life sciences sector and enhanced access to new medicines and treatments for Canadians.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 50 companies who invest nearly $1.4 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
– 30 –
For further information:
Director, Media Relations & Content
E-mail: [email protected]